Patents. Law. Pharma.

BLOG

Zachary Silbersher Zachary Silbersher

Can MSN’s fight for generic Cabometyx affect entry of the generics who already settled with Exelixis?

I previously blogged several times about Exelixis’ patent fight to delay entry of MSN’s generic formulation for Cabometyx. Since that time, a number of additional generics have sought to gain entry. To date, Exelixis has settled with most of the generics for Cabometyx by granting them entry in January 2031. MSN, by contrast, has yet to settle, and continues to litigate against Exelixis. How will MSN’s fight affect entry of the other generics who have already settled?

Read More